A few good peptides: MHC class I-based cancer immunosurveillance and immunoevasion
The remarkable success of immune checkpoint inhibitors demonstrates the potential of
tumour-specific CD8+ T cells to prevent and treat cancer. Although the number of lives …
tumour-specific CD8+ T cells to prevent and treat cancer. Although the number of lives …
[PDF][PDF] The translational challenges of precision oncology
The translational challenges in the field of precision oncology are in part related to the
biological complexity and diversity of this disease. Technological advances in genomics …
biological complexity and diversity of this disease. Technological advances in genomics …
[PDF][PDF] The microbial metabolite trimethylamine N-oxide promotes antitumor immunity in triple-negative breast cancer
H Wang, X Rong, G Zhao, Y Zhou, Y Xiao, D Ma, X Jin… - Cell metabolism, 2022 - cell.com
Immunotherapy has achieved limited success in patients with triple-negative breast cancer
(TNBC), an aggressive disease with a poor prognosis. Commensal microbiota have been …
(TNBC), an aggressive disease with a poor prognosis. Commensal microbiota have been …
[PDF][PDF] Meta-analysis of tumor-and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition
Checkpoint inhibitors (CPIs) augment adaptive immunity. Systematic pan-tumor analyses
may reveal the relative importance of tumor-cell-intrinsic and microenvironmental features …
may reveal the relative importance of tumor-cell-intrinsic and microenvironmental features …
Improved prediction of immune checkpoint blockade efficacy across multiple cancer types
Only a fraction of patients with cancer respond to immune checkpoint blockade (ICB)
treatment, but current decision-making procedures have limited accuracy. In this study, we …
treatment, but current decision-making procedures have limited accuracy. In this study, we …
[PDF][PDF] Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy
C Krishna, RG DiNatale, F Kuo, RM Srivastava… - Cancer cell, 2021 - cell.com
Clear cell renal cell carcinomas (ccRCCs) are highly immune infiltrated, but the effect of
immune heterogeneity on clinical outcome in ccRCC has not been fully characterized. Here …
immune heterogeneity on clinical outcome in ccRCC has not been fully characterized. Here …
[HTML][HTML] Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors
Abstract Treatment with immune checkpoint inhibitors (ICI) has demonstrated clinical benefit
for a wide range of cancer types. Because only a subset of patients experience clinical …
for a wide range of cancer types. Because only a subset of patients experience clinical …
Germline variants associated with toxicity to immune checkpoint blockade
Immune checkpoint inhibitors (ICIs) have yielded remarkable responses but often lead to
immune-related adverse events (irAEs). Although germline causes for irAEs have been …
immune-related adverse events (irAEs). Although germline causes for irAEs have been …
[PDF][PDF] MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells
E Limagne, L Nuttin, M Thibaudin, E Jacquin… - Cancer Cell, 2022 - cell.com
Chemotherapy with anti PD-1/PD-L1 antibodies has become the standard of care for
patients with metastatic non-small cell lung cancer (mNSCLC). Using lung tumor models …
patients with metastatic non-small cell lung cancer (mNSCLC). Using lung tumor models …
[HTML][HTML] Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial
Mesothelioma is a rare and fatal cancer with limited therapeutic options until the recent
approval of combination immune checkpoint blockade. Here we report the results of the …
approval of combination immune checkpoint blockade. Here we report the results of the …